| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Anhui Wanbang Pharmaceutical Technology Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥36.76 |
| 52 Week High | CN¥90.00 |
| 52 Week Low | CN¥35.30 |
| Beta | 0 |
| 11 Month Change | -9.73% |
| 3 Month Change | -18.67% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -50.32% |
Recent News & Updates
Shareholder Returns
| 301520 | CN Life Sciences | CN Market | |
|---|---|---|---|
| 7D | 3.3% | 5.7% | 1.5% |
| 1Y | n/a | -42.7% | -18.8% |
Return vs Industry: Insufficient data to determine how 301520 performed against the CN Life Sciences industry.
Return vs Market: Insufficient data to determine how 301520 performed against the CN Market.
Price Volatility
| 301520 volatility | |
|---|---|
| 301520 Average Weekly Movement | 6.0% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in CN Market | 8.9% |
| 10% least volatile stocks in CN Market | 3.8% |
Stable Share Price: 301520's share price has been volatile over the past 3 months.
Volatility Over Time: 301520's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | Chunlei Tao | www.ahwbyy.cn |
Anhui Wanbang Pharmaceutical Technology Co.,Ltd. provides drug research and development and clinical trial services for drug manufacturers and marketing authorization holders in China. The company was founded in 2006 and is based in Hefei, China.
Anhui Wanbang Pharmaceutical Technology Co.,Ltd. Fundamentals Summary
| 301520 fundamental statistics | |
|---|---|
| Market cap | CN¥2.45b |
| Earnings (TTM) | CN¥109.30m |
| Revenue (TTM) | CN¥364.03m |
22.4x
P/E Ratio6.7x
P/S RatioIs 301520 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 301520 income statement (TTM) | |
|---|---|
| Revenue | CN¥364.03m |
| Cost of Revenue | CN¥195.74m |
| Gross Profit | CN¥168.29m |
| Other Expenses | CN¥58.98m |
| Earnings | CN¥109.30m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.64 |
| Gross Margin | 46.23% |
| Net Profit Margin | 30.03% |
| Debt/Equity Ratio | 0% |
How did 301520 perform over the long term?
See historical performance and comparison